These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

980 related items for PubMed ID: 17459461

  • 1. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients.
    Li J, Yang W, Wu X.
    Gynecol Oncol; 2007 Jun; 105(3):769-75. PubMed ID: 17459461
    [Abstract] [Full Text] [Related]

  • 2. Outcome and prognostic factors in ovarian germ cell malignancies.
    Lai CH, Chang TC, Hsueh S, Wu TI, Chao A, Chou HH, Wang PN.
    Gynecol Oncol; 2005 Mar; 96(3):784-91. PubMed ID: 15721426
    [Abstract] [Full Text] [Related]

  • 3. Salvage surgery for chemorefractory ovarian germ cell tumors.
    Munkarah A, Gershenson DM, Levenback C, Silva EG, Messing MJ, Morris M, Burke TW.
    Gynecol Oncol; 1994 Nov; 55(2):217-23. PubMed ID: 7959287
    [Abstract] [Full Text] [Related]

  • 4. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.
    Ghaemmaghami F, Hasanzadeh M, Karimi Zarchi M, Fallahi A.
    Int J Surg; 2008 Oct; 6(5):382-6. PubMed ID: 18715834
    [Abstract] [Full Text] [Related]

  • 5. Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors.
    Cicin I, Saip P, Guney N, Eralp Y, Ayan I, Kebudi R, Topuz E.
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):210-4. PubMed ID: 19419810
    [Abstract] [Full Text] [Related]

  • 6. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
    Habuchi T, Kamoto T, Hara I, Kawai K, Nakao M, Nonomura N, Kobayashi T, Ogawa O, Kamidono S, Akaza H, Okuyama A, Kato T, Miki T.
    Cancer; 2003 Oct 15; 98(8):1635-42. PubMed ID: 14534879
    [Abstract] [Full Text] [Related]

  • 7. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M, Miyake H, Hara I, Muramaki M, Takenaka A, Fujisawa M.
    Hinyokika Kiyo; 2007 Dec 15; 53(12):851-6. PubMed ID: 18203521
    [Abstract] [Full Text] [Related]

  • 8. [Treatment outcome of children and adolescents with germ cell tumor after combined therapy---a report of 44 cases].
    Sun XF, Yang QY, Zhen ZJ, Xia Y, Huang ZH, Ling JY.
    Ai Zheng; 2006 Dec 15; 25(12):1529-32. PubMed ID: 17166380
    [Abstract] [Full Text] [Related]

  • 9. [Comprehensive staging surgery in treatment of malignant ovarian germ cell tumor].
    Jin Y, Pan LY, Huang HF, Shen K, Wu M, Yang JX, Lang JH.
    Zhonghua Fu Chan Ke Za Zhi; 2005 Dec 15; 40(12):826-30. PubMed ID: 16412329
    [Abstract] [Full Text] [Related]

  • 10. [Treatment of non-testicular germ cell tumors in children and adolescents with BEP and VIP: initial results of the MAKEI 89 therapy study].
    Göbel U, Bamberg M, Engert J, Gnekow AK, Haas HJ, Jürgens H, Kühl J, Lenard HG, Lumenta C, Niethammer D.
    Klin Padiatr; 1991 Dec 15; 203(4):236-45. PubMed ID: 1719267
    [Abstract] [Full Text] [Related]

  • 11. Malignant ovarian germ cell tumors: a single-institution experience.
    Cicin I, Eralp Y, Saip P, Ayan I, Kebudi R, Iyibozkurt C, Tuzlali S, Gorgun O, Topuz E.
    Am J Clin Oncol; 2009 Apr 15; 32(2):191-6. PubMed ID: 19307952
    [Abstract] [Full Text] [Related]

  • 12. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor.
    Kang H, Kim TJ, Kim WY, Choi CH, Lee JW, Kim BG, Bae DS.
    Gynecol Oncol; 2008 Oct 15; 111(1):106-10. PubMed ID: 18656249
    [Abstract] [Full Text] [Related]

  • 13. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM, Moore KN, Myers TK, Lanneau GS, McMeekin DS, Walker JL, Gold MA.
    Gynecol Oncol; 2009 Feb 15; 112(2):337-41. PubMed ID: 19041126
    [Abstract] [Full Text] [Related]

  • 14. [BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89].
    Göbel U, Calaminus G, Teske C, Bamberg M, Bökkerink JP, Haas RJ, Holschneider AM, Janka-Schaub G, Jürgens H, Mittler U.
    Klin Padiatr; 1993 Feb 15; 205(4):231-40. PubMed ID: 7690864
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors.
    Kesler KA, Rieger KM, Hammoud ZT, Kruter LE, Perkins SM, Turrentine MW, Schneider BP, Einhorn LH, Brown JW.
    Ann Thorac Surg; 2008 Feb 15; 85(2):371-8. PubMed ID: 18222228
    [Abstract] [Full Text] [Related]

  • 19. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma.
    McCreath WA, Eisenhauer EL, Abu-Rustum NR, Venkatraman ES, Caceres A, Bier R, Huh J, Cho J, Barakat RR, Chi DS.
    Gynecol Oncol; 2006 Jul 15; 102(1):8-14. PubMed ID: 16427689
    [Abstract] [Full Text] [Related]

  • 20. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
    Cheng X, Jiang R, Li ZT, Tang J, Cai SM, Zhang ZY, Tian WJ, Zang RY.
    Eur J Surg Oncol; 2009 Oct 15; 35(10):1105-8. PubMed ID: 19443175
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.